REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
19/01/2026
Voltar para busca
Dado oficial do USPTO
EXO-NET
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
26
Atualização mais recente
20/01/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
08/11/2019
Data de registro
19/01/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/01/2021
Última transação
20/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
83
Localização do titular
AU
Examinador
LAM,HAI-LY HUYNH
Unidade examinadora
N10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Sienna Cancer Diagnostics Ltd
Representantes
Charles G. Zug Nelson Mullins Riley & Scarborough LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations and substances for the treatment and/or diagnosis of cancer and infectious diseases; biotechnologically-formed enzyme preparations for medical purposes; medicinal preparations for the treatment of cancer and infectious diseases; monoclonal antibodies for therapeutic purposes; products containing antibodies for use in medicinediagnostic kits consisting primarily of monoclonal antibodies used in the capture of exosomes and other extra cellular vesicles for use in disease testing; proteins for binding antibodies for medical use; proteins for detecting antibodies for medical use; reagents for medical usefor use in the development of monoclonal antibodies; diagnostic biomarker reagents for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancerviralbacterial infection; vaccines for human use; diagnostic preparations and reagents for medical purposes; vaccine adjuvants; diagnostic preparationsreagentssubstances for medical purposes; diagnostic products and testing materials for medical purposesdiagnostic kits consisting primarily of monoclonal antibodiesbuffersreagents for use in capturing and purifying exosomes and other extra cellular vesicles for use in disease testing; reagents for use in diagnostic tests for medical purposes; medical diagnostic reagents for capturing and purifying exosomes and other extra cellular vesicles that can be utilised in therapeutics or diagnostics; cells for growing recombinant human protein for medical purposes; recombinant DNA technology proteins for medical use; biological reagents for use in molecular biologyreagents for medical use for capturing and purifying exosomes and other extra cellular vesicles that contain nucleic acid; antibodies that are specifically able to bind and capture exosomes and other extra cellular vesicles for medical purposes; antibody fragments that are specifically able to bind and capture exosomes and other extra cellular vesicles for medical purposes; antibody conjugates that are specifically able to bind and capture exosomes and other extra cellular vesicles for medical purposes; pharmaceutical preparations for the treatmentreconstruction and repair of antibodies; immunological antibodies for medical use; monoclonal antibodies for medical diagnostic use; monoclonal antibodies for medical use
Publicações
Histórico de despachos e eventos da marca no USPTO.
26 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
16/05/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
24/04/2021
FIMP
FINAL DISPOSITION PROCESSED
23/04/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
19/04/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
29/01/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
19/01/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/11/2020
PUBO
PUBLISHED FOR OPPOSITION
03/11/2020
GPNX
NOTIFICATION PROCESSED BY IB
02/11/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
14/10/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
14/10/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/10/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
24/09/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/09/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/09/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/09/2020
RFNT
REFUSAL PROCESSED BY IB
27/03/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/03/2020
RFRR
REFUSAL PROCESSED BY MPU
09/03/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/02/2020
CNRT
NON-FINAL ACTION WRITTEN
18/02/2020
DOCK
ASSIGNED TO EXAMINER
12/02/2020
MAFR
APPLICATION FILING RECEIPT MAILED
27/12/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
23/12/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
19/12/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace EXO-NET ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.